JP2020511468A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511468A5
JP2020511468A5 JP2019550653A JP2019550653A JP2020511468A5 JP 2020511468 A5 JP2020511468 A5 JP 2020511468A5 JP 2019550653 A JP2019550653 A JP 2019550653A JP 2019550653 A JP2019550653 A JP 2019550653A JP 2020511468 A5 JP2020511468 A5 JP 2020511468A5
Authority
JP
Japan
Prior art keywords
disease
fibrosis
syndrome
disorder
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511468A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022545 external-priority patent/WO2018170201A1/en
Publication of JP2020511468A publication Critical patent/JP2020511468A/ja
Publication of JP2020511468A5 publication Critical patent/JP2020511468A5/ja
Pending legal-status Critical Current

Links

JP2019550653A 2017-03-16 2018-03-15 Mk2阻害剤の重水素化アナログおよびその使用 Pending JP2020511468A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472022P 2017-03-16 2017-03-16
US62/472,022 2017-03-16
PCT/US2018/022545 WO2018170201A1 (en) 2017-03-16 2018-03-15 Deuterated analogs of mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2020511468A JP2020511468A (ja) 2020-04-16
JP2020511468A5 true JP2020511468A5 (enExample) 2021-04-22

Family

ID=63523341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550653A Pending JP2020511468A (ja) 2017-03-16 2018-03-15 Mk2阻害剤の重水素化アナログおよびその使用

Country Status (4)

Country Link
US (1) US11230551B2 (enExample)
EP (1) EP3596085A4 (enExample)
JP (1) JP2020511468A (enExample)
WO (1) WO2018170201A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Mk2阻害剤の重水素化アナログおよびその使用
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN115925718A (zh) * 2022-12-27 2023-04-07 瑞石生物医药有限公司 一种四环内酰胺衍生物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010533674A (ja) 2007-07-16 2010-10-28 ノバルティス アーゲー Mk2阻害剤として有用なヘテロ環式化合物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
US9457707B2 (en) * 2014-09-15 2016-10-04 Nissan North America, Inc. Vehicle auxiliary lamp unit
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Mk2阻害剤の重水素化アナログおよびその使用
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor

Similar Documents

Publication Publication Date Title
JP2020512315A5 (enExample)
JP2020514361A5 (enExample)
JP2020514360A5 (enExample)
ES2988336T3 (es) Un agente antineoplásico 1-((4-(4-fluoro-2-metil-1H-indol-5-iloxi)-6-metoxiquinolin-7-iloxi)metil)ciclopropanamina, su forma cristalina y sus sales
CN109071448B (zh) Ask1抑制剂及其制备方法和应用
CN111471021B (zh) 取代的二氨基甲酰胺和二氨基甲腈嘧啶,其组合物,和用其治疗的方法
JP2024113019A5 (enExample)
JP2020523390A5 (enExample)
JP2013545812A5 (enExample)
JP2022542434A5 (enExample)
JP2019524660A5 (enExample)
CA3019450A1 (en) Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application
JP2022531088A5 (enExample)
JP6830888B2 (ja) Jak阻害剤の硫酸水素塩の結晶形およびその製造方法
TW201841910A (zh) 胺吡啶衍生化合物之鹽類、其結晶形及其製備方法
CN111770914A (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
JP2007509043A5 (enExample)
ES2817448T3 (es) Compuestos de pirimidina como inhibidores de quinasas
JP2022521413A5 (enExample)
JP2019507776A (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
TW200835686A (en) Novel compounds 621
ES2340201T3 (es) Moduladores de hexahidro-ciclooctilpirazol cannabinoides.
TW200800211A (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
EP2516420B1 (en) Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
CA2813580A1 (en) Substituted pyridazine carboxamide compounds as kinase inhibitor compounds